Lantheus Holdings, Inc. (NASDAQ:LNTH) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday, July 5th.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
Separately, Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Lantheus Holdings in a research report on Wednesday, April 26th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Lantheus Holdings has an average rating of “Buy” and a consensus price target of $15.60.
Shares of Lantheus Holdings (NASDAQ:LNTH) opened at 19.15 on Wednesday. Lantheus Holdings has a 52-week low of $3.46 and a 52-week high of $19.15. The firm has a market capitalization of $713.59 million, a P/E ratio of 32.13 and a beta of 0.93. The stock’s 50 day moving average is $17.01 and its 200-day moving average is $13.37.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 2nd. The medical equipment provider reported $0.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.09. The firm had revenue of $81.36 million for the quarter, compared to analyst estimates of $77.75 million. Lantheus Holdings had a net margin of 6.71% and a negative return on equity of 24.06%. On average, equities analysts forecast that Lantheus Holdings will post $0.93 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/07/25/lantheus-holdings-inc-lnth-stock-rating-lowered-by-zacks-investment-research-updated-updated.html.
In other Lantheus Holdings news, insider Michael P. Duffy sold 20,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $15.42, for a total value of $308,400.00. Following the transaction, the insider now directly owns 188,234 shares in the company, valued at $2,902,568.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Avista Capital Partners Gp, Ll sold 3,000,000 shares of the company’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $13.40, for a total transaction of $40,200,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,060,000 shares of company stock worth $85,757,800. 2.30% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new position in Lantheus Holdings during the first quarter valued at approximately $332,000. Parametric Portfolio Associates LLC increased its position in Lantheus Holdings by 28.9% in the first quarter. Parametric Portfolio Associates LLC now owns 22,530 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 5,058 shares during the period. Bank of New York Mellon Corp increased its position in Lantheus Holdings by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after buying an additional 4,084 shares during the period. Algert Global LLC acquired a new position in Lantheus Holdings during the first quarter valued at approximately $357,000. Finally, Capital One National Association increased its position in Lantheus Holdings by 7.7% in the first quarter. Capital One National Association now owns 69,050 shares of the medical equipment provider’s stock valued at $863,000 after buying an additional 4,925 shares during the period. Hedge funds and other institutional investors own 64.83% of the company’s stock.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.